Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: Implications for specific immunotherapy
Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: Implications for specific immunotherapy
复制标题
DOI：
10.1016/j.urology.2005.11.052
复制
发表时间：
2006-05-01
期刊：
影响因子：
2.1
通讯作者：
Tsukamoto, Taiji
中科院分区：
文献类型：
--
作者：
Kitamura, Hiroshi;Torigoe, Toshihiko;Tsukamoto, Taiji
目标.目的检测Survivin在膀胱移行细胞癌中的表达，探讨Survivin是否为膀胱移行细胞癌特异性抗原，是否可作为膀胱移行细胞癌免疫治疗的靶点。Survivin是凋亡抑制因子家族的成员之一，在多种肿瘤中表达，但在正常成人组织中不表达。对88例经尿道电切和根治性膀胱癌患者的标本进行了Survivin和人类白细胞抗原（HLA）I类的免疫组织化学染色。为了确定生存素是否被宿主免疫系统识别为肿瘤抗原，我们采用酶联免疫吸附试验检测了52例患者和18例健康志愿者血清中的抗生存素抗体。88例膀胱癌标本中Survivin和HLA I类抗原分别有77例（87.5%）和59例（67.0%）表达，56例（63.6%）同时表达。膀胱癌患者血清中抗Survivin抗体的吸光度值显著高于健康志愿者。血清中抗Survivin抗体水平与Survivin在大肠癌组织中的表达强度存在相关性。Survivin在膀胱癌中有高敏感性表达。提示64%的膀胱癌患者生存素存在于抗原提呈细胞的HLA I类分子上。以生存素为靶点治疗膀胱癌是未来的可能性。
Objectives. To assess the expression of survivin in transitional cell carcinoma of the bladder and to study whether survivin is a transitional cell carcinoma-specific antigen that could be a target for immunotherapy. Survivin, an inhibitor of apoptosis family member, has been reported to be expressed in various cancers but not in normal adult tissues.Methods. Immunohistochemical staining for survivin and human leukocyte antigen (HLA) class I was performed on specimens from 88 patients who underwent transurethral resection and radical cystectomy. To determine whether survivin was recognized as a tumor antigen by the host immune system, we assessed anti-survivin antibodies in the sera of 52 patients and 18 healthy volunteers with an enzyme-linked immunosorbent assay using recombinant survivin.Results. Survivin and HLA class I were expressed in 77 (87.5%) and 59 (67.0%) of the 88 bladder cancer specimens, respectively, and 56 (63.6%) expressed both survivin and HLA class I. The absorbance values of anti-survivin antibodies in patients with bladder cancer were significantly greater than those in the healthy volunteers. A relationship was found between the level of serum anti-survivin antibodies and the staining intensity of survivin in the specimen.Conclusions. Survivin is expressed in carcinoma of the bladder with high sensitivity. It is suggested that survivin is presented on HLA class I molecules of antigen-presenting cells in 64% of patients with bladder cancer. Therapeutic targeting of survivin in bladder cancer is a future possibility.